Evidence map›Paper›PMID 39738793›Full record

Observational studyGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2025

Prevalence and clinicopathological features of microsatellite instability-high metastatic or recurrent gastric and esophagogastric junction cancer: WJOG13320GPS.

Azusa Komori, Shuichi Hironaka, Shigenori Kadowaki, Seiichiro Mitani, Mitsuhiro Furuta, Takeshi Kawakami, Akitaka Makiyama, Naoki Takegawa, Keiji Sugiyama, Hidekazu Hirano and 15 more

Abstract readMulticenter StudyObservational Study
PubMed Publisher
In one paragraph

Observational study in Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. An observational study of the effectiveness and safety of nivolumab plus chemotherapy for untreated advanced or recurrent gastric cancer in Japanese real-world settings: the G-KNIGHT study.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2025
    Observational
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Azusa KomoriDepartment of Gastrointestinal Medical Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan.
Shuichi HironakaDepartment of Medical Oncology, Faculty of Medicine, Kyorin University, Mitaka, Japan. shuichi-hironaka@ks.kyorin-u.ac.jp.ORCID 0000-0001-9714-231X
Shigenori KadowakiDepartment of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
Seiichiro MitaniDepartment of Medical Oncology, Faculty of Medicine, Kindai University, Osakasayama, Japan.
Mitsuhiro FurutaDepartment of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan.
Takeshi KawakamiDivision of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Akitaka MakiyamaCancer Center, Gifu University Hospital, Gifu, Japan.
Naoki TakegawaDepartment of Gastroenterology, Hyogo Cancer Center, Akashi, Japan.
Keiji SugiyamaDepartment of Medical Oncology, National Hospital Organization, Nagoya Medical Center, Nagoya, Japan.
Hidekazu HiranoDepartment of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tsukiji Campus, Chuo-Ku, Japan.
Takayuki AndoThird Department of Internal Medicine, University of Toyama, Toyama, Japan.
Tomohiro MatsushimaDepartment of Gastroenterology, Saitama Prefectural Cancer Center, Ina, Japan.
Akihiko ChidaDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
Tomomi KashiwadaDepartment of Medical Oncology, Saga-Ken Medical Centre Koseikan, Saga, Japan.
Masato KomodaDepartment of Gastrointestinal and Medical Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Toshihiko MatsumotoDepartment of Medical Oncology, Kobe City Medical Center General Hospital, Kobe, Japan.
Hisanobu OdaDivision of Integrative Medical Oncology, Saiseikai Kumamoto Hospital, Kumamoto, Japan.
Hiroshi YabusakiDepartment of Gastroenterological Surgery, Niigata Cancer Center Hospital, Niigata, Japan.
Hisato KawakamiDepartment of Medical Oncology, Faculty of Medicine, Kindai University, Osakasayama, Japan.
Kentaro YamazakiDivision of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Narikazu BokuDepartment of Oncology and General Medicine, IMSUT Hospital, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
Ichinosuke HyodoDepartment of Gastrointestinal Medical Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan.
Kenichi YoshimuraMedical Center for Translational and Clinical Research, Hiroshima University Hospital, Hiroshima, Japan.
Kei MuroDepartment of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
West Japan Oncology Group (WJOG)

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMicrosatellite instability (MSI)-high tumors represent a distinct, small-fraction subtype in esophagogastric junction cancer or gastric cancer (GC), yet their clinical significance remains poorly understood. This study aimed to investigate the prevalence and clinicopathological features of chemotherapy-naïve metastatic or recurrent MSI-high GC as a prescreening study for a phase II trial of nivolumab plus ipilimumab.

methodsKey inclusion criteria included metastatic or recurrent adenocarcinoma of GC, ECOG performance status of 0 or 1, and no prior systemic therapy for metastatic or recurrent disease. MSI status was tested using multiplex PCR fragment analysis (MSI Testing Kit, FALCO). The primary endpoint was the prevalence of MSI-high GC.

resultsBetween October 2020 and October 2022, 930 eligible patients from 75 centers in Japan were analyzed. The prevalence of MSI-high GC was 5.6% (95% CI 4.2-7.3). MSI-high GC was more frequently observed in females than males (9.6% vs 3.8%, p < 0.001), patients aged ≥ 70 years compared to those < 70 years (8.0% vs 2.8%, p < 0.001), in the lower stomach than other locations (10.5% vs 3.2%, p < 0.001), HER2-negative tumors than HER2-positive tumors (6.5% vs 1.8%, p = 0.02), and in patients without liver metastasis than those with liver metastasis (6.9% vs 2.2%, p = 0.004).

conclusionsThe prevalence of MSI-high tumors among chemotherapy-naïve patients with unresectable GC was 5.6%. These tumors were associated with female sex, older age, lower stomach, HER2-negative, and absence of liver metastasis. These findings would help assuming MSI-high tumors and may have significant implications for clinical practice and studies targeting this GC subtype.

Indexed as

AdenocarcinomaEsophageal NeoplasmsEsophagogastric JunctionMicrosatellite InstabilityNeoplasm Recurrence, LocalStomach NeoplasmsAdultAgedAged, 80 and overClinical Trials, Phase II as TopicFemaleHumansJapanMaleMiddle AgedPrevalenceGastric cancerMetastasisMicrosatellite instability

Identifiers

PMID39738793

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.